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                                          INTRODUCTION 
                Malignant biliary obstruction comprises of malignancies causing 
proximal malignant obstruction like Gallbladder carcinoma, hilar 
cholangiocarcinoma, node causing obstruction and malignancies causing 
distal malignant biliary obstruction including pancreatic malignancy, 
ampullary adenocarcinoma, distal cholangiocarcinoma and duodenal 
adenocarcinoma. 
 Most of the patients present in the late inoperable stage where 
palliation alone is possible. Palliation of jaundice is done by 3 methods. 
(1)  Endoscopic stenting. 
(2) Surgical drainage 
(3) Percutaneous drainage 
 Endoscopic method is the most preferred because of the ease, 
physiologically least disturbing, with high success rate and negligible 
morbidity and mortality. Surgical drainage and percutaneous drainage are 
used in select situations, usually when the endoscopic stenting fails. 
 Endoscopic stenting in the preoperative setting is controversial. 
While some studies suggest negative benefit, it is generally accepted in 
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select circumstances like anticipated delay in surgery, cholangitis, renal 
failure, pruritis. 
 Both plastic and metallic stents are available for endoscopic 
palliation. SEMS are the standard in patients in whom expected life 
expectancy more than 6 months, plastic stents are preferred in patients 
whose life expectancy is less than 6 months and also in preoperative 
setting, due to low cost, but the disadvantage is frequent clogging and 
subsequent need for stent exchanges. To overcome this either 3 monthly 
exchange or demand exchange is advocated. Most experts would agree for 










REVIEW OF LITERATURE 
EPIDEMIOLOGY 
 The incidence of pancreatic and biliary malignancies increases with 
age and, in fact, these tumors are rarely seen before the age of 45. 
Epidemiological surveys have shown that the median age of diagnosis 
approximates 70 years.  
 Diabetes, chronic pancreatitis, pernicious anemia, inherited disorders 
such as familial adenomatous polyposis, and high fat and meat intake have 
been cited as risk factors for pancreatic cancer. Patients with hereditary and 
familial pancreatic cancer have upto 40% life time risk of pancreatic 
cancer1. 
 The majority of cases of cholangiocarcinoma have no identifiable 
underlying etiology. 
 Choledochal cysts are associated with a 10% lifetime incidence  
of cholangiocarcinoma; there is a 1% per year risk which plateaus after  
15-20 years. 
 Cholangiocarcinoma is also rarely seen in association with cirrhosis 
and has been weakly linked to hepatitis C infection. 
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 Tumors at the biliary confluence of the liver are the most common 
and comprise 40-60% of the total. Middle third and distal third tumors 
comprise 17-20% and 18-27%, respectively. A small percentage of patients 
(<10%) have diffuse tumors involving the entire extrahepatic bile duct. 
 Among neoplasms involving the biliary tree, carcinoma of the 
gallbladder has the poorest prognosis with a 5 year survival ranging 
between 0% and 10% in most reported series2.  
 Cholelithiasis is thought to be an important risk factor for gallbladder 
cancer. Other risks factors such as the presence of a porcelain gallbladder, 
gallbladder polyps, an anomalous pancreatiocobiliary junction and obesity 
have also been suggested in epidemiological studies3. 
Natural History  
 The most common malignancy causing distal biliary malignant 
obstruction is pancreatic cancer accounting for more than 90% of cases 
followed by gallbladder cancer, malignant lymphadenopathy and 
cholangiocarcinoma, the latter being relatively uncommon in Western 
countries. 
 Except for extrinsic compressions caused by enlarged lymph nodes 
in the case of hematological malignancies such as Non-Hodgkin’s 
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lymphomas and for ampullary tumors, the majority of patients are found 
with unresectable disease have a median survival of 3-5 months4. 
Clinical Features  
 The most common presenting symptoms of pancreaticobiliary 
malignancies are painless jaundice, anorexia and weight loss. If pain occurs 
it is often located in the epigastric region or right upper quadrant, and may 
radiate to the back. Back pain usually indicates retroperitoneal infiltration 
by the tumor and therefore probable unresectability. Other symptoms may 
include dark urine, pale stools and pruritus. As many as 80% of patients 
with pancreatic cancer will present with impaired glucose tolerance or 
frank diabetes mellitus. Carcinoma of the body and tail of the pancreas 
presents with similar features, although jaundice is usually absent or 
develops very late in the course of the disease. A complete physical 
examination, including assessment for abnormal lymph nodes, jaundice, 
hepatomegaly, palpable gallbladder, or mass should be performed. Chest 
radiograph may be appropriate to exclude pulmonary metastases. Obtaining 
serum tumor markers such as CA 19-9 and CEA may be appropriate. Once 
there is a clinical suspicion of a pancreaticobiliary malignancy, further 
investigation with abdominal imaging studies is appropriate. 
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Most prevalent distal pancreaticobiliary Malignancies 
 Ampullary adenocarcinoma 
 Pancreatic adenocarcinoma (Head) 
 Cholangiocarcinoma (non hilar) 
 Metastatic disase 
Ampullary Carcinoma 
 Ampullary carcinoma is suspected based upon the demonstration of 
obstructive jaundice, often with dilation of the pancreatic and biliary ducts 
seen on abdominal imaging studies. A discrete mass may or may not be 
identifiable by using standard transabdominal US (TUS) or helical 
computerized tomography (CT) scanning. ERCP allows for direct 
identification and biopsy confirmation, although the diagnostic accuracy of 
biopsy is not 100%. MRCP may allow identification of the lesion and 
obviate diagnostic ERCP. Endoscopic ultrasound (EUS) allows for more 
accurate diagnosis and staging of these lesions than CT, and also allows for 
fine needle aspirate (FNA) tissue sampling. EUS also may facilitate the 
selection of patients who can undergo local resection instead of 
pancreaticoduodenectomy (Whipple operation). Once the lesion is 
identified and staged, the choice of operative resection for cure or some 
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form of jaundice palliation are similar to treatment options for carcinoma of 
the pancreatic head. 
Pancreatic malignancies 
 The approach to the patient with pancreatic carcinoma involving the 
pancreatic head is different from the patient with body/tail lesions in terms 
of accessibility, curative potential, and palliation. 
 Most patients with cancer of the pancreatic head present with 
obstructive jaundice. Radiological imaging studies are performed allowing 
for (a) detection of the tumor, (b) determination of tumor respectability, 
and (c) tissue acquisition under imaging guidance. 
 TUS will suggest biliary obstruction by the demonstration of biliary 
ductal dilation. It may also identify the presence of obvious liver 
metastases. However, standard TUS is operator dependent and has a poor 
sensitivity for detecting small neoplasms of the pancreatic head. Recent 
advances in TUS, such as color Doppler US, US angiography, harmonic 
imaging (tissue harmonic imaging and contrast harmonic imaging), and 
three-dimensional US, may improve the usefulness of this modality in the 
staging of pancreatic cancer. Nonetheless, more information regarding 
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staging and extent of disease, and possible nodal or vascular involvement is 
obtainable with other imaging modalities. 
 Helical CT of the abdomen with fine cuts through the pancreas 
during the arterial and portal phases of contrast enhancement has a high 
sensitivity and specificity for the detection of pancreatic carcinoma. It 
allows for the determination of tumor extension, liver metastases, and 
invasion of vascular structures, and thus, resectability. Multislice 
(multidetector) CT has been introduced and may improve on the accuracy 
of helical CT. If the CT findings are  found to be highly suggestive of a 
resectable pancreatic carcinoma  in the appropriate clinical setting, and the 
patient is felt to be an  operative candidate, a reasonable approach is to then 
refer the patient  directly for an attempt at surgical resection 
(pancreaticoduodenectomy) with or without further imaging (depending on 
local availability and expertise) or diagnostic testing. Transabdominal or 
CT-guided biopsy of the pancreatic mass rarely may result in tumor 
seeding at the needle track or within the peritoneum and has been reported 
to increase the risk of postoperative recurrence. If the CT scan reveals overt 
evidence of unresectable pancreatic cancer or the patient is a  
nonoperative candidate because of co-morbid medical conditions,  
non-operative palliation of obstructive jaundice should be performed at 
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ERCP. If a definitive tissue diagnosis is required for the administration of 
chemotherapy and/or radiation therapy, tissue acquisition can be performed 
at the time of the palliative ERCP. If a tissue diagnosis cannot be made at 
that time, then EUS-guided FNA of the mass or metastatic sites should be 
performed.  
Magnetic resonance imaging (MRI) of the pancreas may include 
MRI, MR cholangiopancreatography (MRCP), or magnetic resonance 
angiography. Standard abdominal MRI appears to be an accurate modality 
for staging pancreatic carcinoma, though it does not appear to be more 
specific or sensitive than helical CT. In addition, it is more expensive and 
more time consuming to perform than CT. 
If expertise in EUS is readily available, it should be used as a 
preoperative staging modality in patients with suspected pancreatic cancer. 
This is particularly important in patients with equivocal findings on CT .or 
those with co-morbidities and, therefore, at higher risk for intra operative or 
postoperative complications. EUS allows identification of vascular 
invasion as well as sampling of suspicious-appearing lymph nodes, which, 
if positive, may change the treatment approach as it alters prognosis. EUS  
appears to be complementary to helical CT, with EUS better at detecting 
small (<3 cm) masses, staging the portal vein, and detecting lymph node 
 10 
metastases, while helical CT is superior for staging arterial involvement 
and distant metastases. An EUS-guided FNA biopsy specimen allows for a 
definitive tissue diagnosis of a pancreatic mass when results on other 
biopsy methods are negative but pancreatic cancer is suspected. If EUS 
suggests resectability, EUS- guided biopsy of the mass is not necessary 
before proceeding with operative resection, although this point remains 
controversial. Advantages of needle biopsy of the mass include 
identification of alternative diagnoses to primary pancreatic 
adenocarcinoma (lymphoma, islet cell tumors and metastatic disease). It 
also allows for preoperative patient counselling. Potential disadvantages of 
preoperative EUS-guided FNA include the risks of pancreatitis, bleeding, 
and, theoretically, tumor seeding. The latter has never been reported and 
appears to be inconsequential in most cases since the needle path usually 
lies within the resected specimen. Ideally, EUS should be performed before 
ERCP and stent placement since the latter may interfere with the accuracy 
of EUS staging and EUS findings of unresectable carcinoma allow 
improved patient selection for placement of a self-expanding metallic stent. 
In patients with unresectable cancer, EUS-guided celiac plexus neurolysis 
has been shown to control disabling abdominal pain.  
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The near-pathognomonic findings on ERCP of a pancreatic head 
cancer are strictures of the bile and pancreatic ducts with proximal dilation 
(the “double-duct” sign). While ductal abnormalities are almost invariably 
present in patients with adenocarcinoma, other imaging modalities (CT, 
MR, and EUS) have supplanted ERCP in the diagnosis of pancreatic 
cancer. Preoperative ERCP does not add further staging information and 
may result in complications that may make operative intervention more 
difficult and/or may considerably delay operative intervention, resulting in 
a decreased potential for curative resection. Furthermore, several studies 
suggest higher postoperative complications when a preoperative ERCP is 
done. However, if the patient suffers from cholangitis or severe pruritus, or 
if there is a substantial delay in operative resection, preoperative ERCP 
with biliary drainage should be performed.  
Cholangiocarcinoma 
 A primary tumor of the bile duct should be suspected based on 
clinical and imaging findings. Abdominal CT scans will show biliary 
dilation without an associated pancreatic mass or pancreatic ductal dilation, 
and the level of obstruction usually can be localized to a level above that of 
the pancreatic duct. The differentiation of hilar vs non-hilar tumors is 
important because of implications for both operative resection and 
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endoscopic palliation. The Bismuth classification of cholangiocarcinoma is 
useful for determining surgical resectability and type of surgery. If imaging 
studies map the level of obstruction below the bifurcation (Bismuth type 1 
lesions), operative resection should be considered in fit patients without 
metastatic disease. If the patient is a poor operative candidate, palliation 
with plastic or metal stents, as with pancreatic carcinoma, should be 
undertaken.  
Metastatic disease 
 Metastatic disease may lead to biliary obstruction either intrinsically 
or extrinsically (porta hepatic involvement) any where from the level of the 
bifurcation to the ampulla. The diagnosis may be obvious, based upon 
known widespread malignancy, or more occult and discovered at the time 
of endoscopic evaluation or surgical resection. CT scan findings may 
mimic primary malignant disease of the bile ducts or pancreas. An MR 
examination may be useful in defining the presence of perihilar obstructive 
disease. If disease is widespread, palliation of obstruction is indicated as for 




Anatomical classification of Hilar Cholangiocarcinoma 
 The extent of duct involvement by perihilar tumors may be classified 
as suggested by Bismuth and Corlette. 
A. Type 1 : tumors below the confluence of the left and right hepatic 
ducts (ceiling of the biliary confluence is intact; right and 
left ductal systems communicate); 
B. Type II : tumors reaching the confluence but not involving the left 
or right hepatic ducts (ceiling of the confluence is 
destroyed; bile ducts are separated); 
C. Type III : tumors occluding the common hepatic duct and either the 
right (IIIa) or left (IIIb) hepatic duct; 
D. Type IV : multicentric tumors or tumors involving the confluence 
and both hepatic ducts, the right one and the left one. 
Malignant Hilar Strictures 
 Cholangiocarcinoma 
 Gallbladder carcinoma 
 Nodal mets at porta hepatis 
 Hepatocellular carcinoma 
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 Hepatic metastases 
 Metastasis to biliary tree 
Criteria for unresectability in patients with hilar cholangiocarcinoma 
 Medical co-morbidities limiting the patient’s ability to undergo 
major surgery. 
 Significant underlying liver disease prohibiting liver resection 
necessary for curative surgery based on preoperative imaging. 
 Bilateral tumor extension to secondary biliary radicals. 
 Encasement or occlusion of the main portal vein. 
 Lobar atrophy with contralateral portal vein involvement. 
 Contralateral tumor extension to secondary biliary radicals. 
 Evidence of metastases to N2 level lymph nodes. 
 Presence of distant metastases. 
Indications for Endoscopic Palliation 
 Biliary decompression is indicated if there is cholangitis or pruritus 
in the face of advanced malignant biliary obstruction. Biliary stenting has 
also been shown to improve symptoms of anorexia and quality of life. 
Routine preoperative drainage of an obstructed biliary system, 
however, has not been shown to benefit patients who will soon undergo a 
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surgical procedure, and may in fact be deleterious in some5,6,7. If 
preoperative drainage is indicated because of cholangitis or an anticipated 
delay to surgery in the face of clinically significant symptoms, such as 
pruritus, drainage has traditionally been performed using plastic stents. 
Plastic endoprostheses 
 Plastic stents are easy to insert, and can be removed if necessary. 
Their biggest advantage compared to metal stents is that their upfront cost 
is significantly lower (tenfold in many markets). A large variety of biliary 
plastic stents are available with internal diameters ranging from 5 to 11.5 
French (Fr) gauge with lengths varying from 5 to 15 centimeters (cm). 
Straight plastic stents with flaps at both ends are the most commonly used. 
The disadvantage of plastic stents is early stent clogging. Recent 
investigations have focused on the importance of ingested fibre matter9 and 
the production of bacterial biofilm10 as the factors responsible for stent 
clogging. 
Methods to overcome stent clogging. 
(1) Size of the internal diameter. 
 The duration of patency for stents with an internal diameter of 10 Fr 
or greater is 21-32 weeks compared to 10-12 weeks for 7 or 8.5 Fr plastic 
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stents. Additionally, there may be a lower associated incidence of 
cholangitis with larger-caliber stents which is attributed to improved 
internal flow dynamics44. There is no conclusive evidence favouring 11.5F 
over 10F stents11. 
(2) Plastic stent design.  
Animal studies suggest straight stent may provide better 
drainage than pigtail stents8. 
Pilot study has assessed a stent without a lumen, that may result in 
prolonged stent patency15. 
(3) Position of the distal tip of the stent. 
 Stents were placed above papilla but stents placed above the papilla 
had higher stent migration rates12. 
(4) Administration of choleretic agents and/or antibiotics. 
 Antibiotics may also be useful by inhibiting bacterial colonization of 
the stent. However, both classes of drugs, alone or in combination, have 
failed to demonstrate improvement in the duration of stent patency13,14.   
In addition, no improvement in survival has been noted. 
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Self-expandable metal stents  
 SEMS are delivered into the bile duct while completely constrained 
by a sheath, allowing insertion as a small-circumference delivery system. 
SEMS differ in regard to the type of delivery system, structural 
composition, design, length and diameter. However, all achieve a much 
larger internal diameter and subsequent longer patency rate compared to 
plastic stents. The mechanisms of SEMS blockage include  
 stent ingrowth 
 over growth by tumor,  
 mucosal hyperplasia. 
 More recently, polyurethane-covered SEMS have been developed in 
the hope of prolonging stent patency by presenting a physical barrier to 
tumor ingrowth. In the sole randomized comparative trial to date, the 
covered SEMS technology was associated with a significant increase in 
patency duration as compared to the uncovered SEMS. However the 
covered SEMS may occlude ductal branches, leading to complications such 
as cholecytitis, cholangitis, and pacreatitis.  
 SEMS are difficult to remove, they are reserved for patients with 
established, unresectable malignant disease, although recently, an 
 18 
increasing number of endoscopists are describing removal of covered 
SEMS. 
PLASTIC Vs METAL STENTS 
Factors Plastic Stent Metallic Stent 
Cost Cheaper Costlier 
Placement Relatively easy More expertise 
Patency 2-4 months 6-8 months 
Long term complication Clogging Tumor ingrowth,  
over grouth 
Management of stent 
obstruction 
Stent exchange Placement of plastic 
stent in SEMS 
Stent choices for palliation of malignant biliary obstruction 
The major decision that needs to be made is the type of stent to be placed 
(plastic or metal). Important measures for this decision include several 
Stent-related factors,  
 such as stent efficacy (relief of jaundice),  
 stent patency,  
 need for reinterventions, and costs.  
Patients-related issues, such as  
 the extent of disease and  
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 expected survival time, also need to be considered and influence the 
optimal and cost-effective choice of stent. 
 Plastic stents and SEMS both provide palliation of jaundice and 
improve liver tests after placement in over 95% of patients.  
Median stent patency ranges  
(A) 2 to 5 months for plastic stent,  
 (B) 4 to 10 months for SEMS16.  
Median patient survival ranges from 4 to 6 months after plastic or 
metallic stenting. The recent Cochrane systematic review, however, did not 
conclude on any survival benefits attributable to metal versus plastic stents. 
 Cost-effectiveness analyses have shown that the optimal choice of 
stent (plastic versus SEMS) is influenced by the ratio of the cost of stent to 
the cost of the ERCP, and the anticipated life expectancy of the patient. The 
greater the cost of the ERCP, the more likely the SEMS will be a cost-
effective choice. Plastic stents may be preferred to SEMS in patients with 
large tumors (>3 cm) or liver metastases, both of which are poor predictors 
of survival, as plastic stents are cost-saving in patients surviving less than 
3-4 months while SEMS are more cost-effective in patients expected to 
survive longer than 6 months17. 
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 SEMS may be preferred in a patient who is non-complaint or resides 
in a remote area without medical access, despite an anticipated short life 
expectancy. 
The optimal stenting strategy 
In a randomized trial, routine exchanges every 3 months were associated 
with longer symptom-free intervals for patients than exchanges at signs of 
stent occlusion, but there was no difference in overall survival17. 
Most cost effective stenting strategy is covered metallic stent and least cost 
effective method is routine 3 monthly replacement of plastic stents18. 
 Occluded SEMS are managed by a variety of methods. The most 
commonly used techniques include  
 insertion of a plastic stent within the occluded SEMS,  
 insertion of a second SEMS and  
 mechanical cleaning of the occluded stent lumen.  
Overall success rates for re-establishing biliary drainage are over 
80%. Given the typical short median survival at the time of the first 
SEMS occlusion, treatment with a plastic prosthesis seems to be the 
most cost-effective method. 
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Percutaneous approach 
 The disadvantages of external biliary drainage include the risk of 
spontaneous catheter dislodgment, inflammation and pain around the 
puncture site, leak of ascitic fluid and bile around the catheter, and loss of 
fluid and electrolytes. 
 Speer and colleagues conducted a prospective, randomized study 
comparing percutaneous and endoscopic drainage. While overall survival 
was not different between either arm, 30-days mortality, both by intention-
to-treat and per-prospective, randomized study comparing percutaneous 
and endoscopic drainage. While overall survival was not different between 
either arm, 30-day mortality, both by intention-to-treat and per protocol 
analysis, was significantly lower in the endoscopy group and justified the 
early termination of the study19. A resent randomized controlled trial 
showed patients treated by percutaneous drainage had longer survival than 
patients treated by endoscopic drainage20. 
 At present, there is insufficient evidence in the literature to advocate 
the routine use of percutaneous drainage as the preferred approach in the 
palliation of patients with distal biliary obstruction other than for reasons of 
institutional expertise or availability. 
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Surgial palliation 
 Historically, surgery was the favored method of palliation, but has 
been replaced by percutaneous and endoscopic insertion of stents14. The  
30-day mortality after surgical palliation for pancreatic cancer and 
cholangiocarcinoma is significant, especially in the face of advancing age 
and metastatic disease. Recent studies have shown that gastrojejunostomy, 
in addition to biliary bypass may decrease the incidence late gastric outlet 
obstruction without higher morbidity or mortality. Surgery has the 
advantage of precluding multiple reinterventions, associated with less 
invasive procedure, namely endoscopic stenting. Most complications 
occurred in the first 30 days in the surgical group. In contrast to the 
endoscopy group, therefore numerically fewer late complications due to 
cholangitis or gastric obstruction. A meta-analysis performed with these 
three studies confirmed a higher likelihood of intervention in the stent 
group21. A recent, single-center, retrospective cost-analysis in the US also 
revealed a striking difference between endoscopic palliation and surgery 
despite the need for repetitive interventions and readmission in the 
endoscopic group22. Surgical bypass remains an excellent alternative and 
may be favored in patients with unresectable disease at the time of 
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laparotomy, and for those requiring concomitant gastrointestinal bypass 
and/or celiac nerve block for management of chronic pain. 
Adjuvant therapy 
 The role of chemotherapy in patients with unresectable disease is 
still limited. 
 An important breakthrough in the management of advanced 
pancreatic cancer occurred with the introduction of gemcitabine and other 
cytotoxic drugs which have been shown to improve major symptoms such 
as pain and weight loss, clinical benefit response, time to progression, and 
length of survival, but maintain an acceptable toxicity profile. 
 The effect of chemotherapy in the management of malignant biliary 
obstruction is unknown. Because tumor invasion into the biliary tree is 
unlikely to be relieved by chemotherapy alone, a procedure to palliate the 
obstruction is still necessary regardless of the administration and response 
to adjuvant therapy, and may in fact be required to improve liver tests and 
function prior to the initiation of this treatment. In contrast, addition of a 
chemotherapeutic regimen for the treatment of patients with unresectable 
disease could potentially result in an improvement in survival and influence 
the choice of palliation. 
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AN APPROACH TO THE MANAGEMENT OF PATIENTS WITH 
DISTAL BILIARY MALIGNANCIES 
 If a pancreaticobiliary malignancy is suspected based on clinical and 
US findings, further imaging must be performed to obtain a diagnosis, 
stage the extent of the malignant process for respectability, and evaluate the 
appropriateness of possible palliative treatment. Identification of the level 
of obstruction is of importance since the differential diagnosis and 
therapeutic implications differ accordingly, conceptually, management may 
be stratified according to whether the biliary obstruction is proximal or 
distal. Patients with a distal CBD obstruction may be amenable to 
endoscopic or surgical drainage, whereas a more proximal blockage of the 
biliary tree may require a more complex intrahepatic anastomosis or 
percutaneous drainage. The optimal approach to patients with malignant 
biliary obstruction must take into account the performance characteristics 
of the different imaging modalities, the level and cause of the obstruction, 
the risk of cholangitis when opacifying an obstructed biliary tree, and the 
potential for curative versus palliative therapy. Recent data suggest that 
non-invasive biliary imaging may greatly assist endoscopic drainage and 
diminish septic complications that occur when there is a failed attempt at 
unilateral or bilateral drainage.  
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Curative Surgery 
 Operable patients with a distal pancreaticobiliary neoplasm and no 
evidence of metastic disease or local vascular invasion should be offered 
curative surgical resection. Unfortunately these patients account for only 
10-20% of all presenting cases. Many elderly patients are not referred for 
consideration of surgery as they are judged unfit for surgery due to 
advanced age or the presence of unrelated co-morbidities. The first step 
towards potential resection should be laparoscopy to determine 
respectability and to prevent a lengthy hospital stay and prolonged 
convalescence associated with an unnecessary laparotomy,  
Laparoscopy is used  
 to detect peritoneal carcinomatosis,  
 liver metastases,  
 malignant ascites, and  
 unexpected cirrhosis.  
Despite an extensive preoperative work-up, 11%-53% of patients were 
found to be unresectable at the time of laparotomy. Most patients thus end 
up undergoing palliative treatment tailored to the symptomatology, i.e. 
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either a surgical bypass (biliary or biliary and gastric), or placement of a 
biliary stent. 
Palliation 
 The three most important conditions requiring treatment is patients 
with unresctable biliary and pancreatic cancers are  
 cholestasis,  
 pain, and  
 gastrointestinal obstruction.  
These may be due to of local tumor invasion into adjacent structures 
including the bile ducts, duodenum, and neural celiac plexus. 
Background 
 Endoscopic placement of plastic biliary stents were first described by 
Soehendra et al. as an alternative to surgical biliary bypass in high-risk and 
inoperable cancer. Self-expandable metal stents (SEMS) for use in the 
biliary system were intorudced into clinical practice over a decade later. 
The ability to place a larger-diameter plastic stent is limited by the size of 
the endoscope accessory channel. SEMS were developed to overcome this 
limitation. They have the advantage of larger diameter stenting (upto 
10mm) but are more costly than plastic stents. 
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Technique of stent implantion  
 The options include draining only the left hepatic system, draining 
only the right hepatic system, or draining both systems. The decision 
whether to place a single biliary stent or multiple stents depends initially on 
the location of the stricture in the biliary tract. In patients who have 
strictures that do not involve the confluence of right and left hepatic ducts 
(Bismuth type I hilar strictures), jaundice can be palliated completely with 
a single biliary stent because both the right and left intrahepatic ductal 
systems are in communication. 
 In patients who have more complex strictures (Bismuth type II to IV 
strictures) the central question is whether adequate palliative relief of 
obstruction requires the placement of two endoprostheses, one to drain the 
left system and other the right, or if one prosthesis placed in either system 
will suffice.  
 Palliation of jaundice generally requires drainage of 1/4 to 1/3 of a 
healthy liver, or proportionally more in those with underlying dysfunction. 
Hence unilateral drainage is usually adequate, and many studies have 
reported good results using a single stent in about 80% of patients with type 
II and III tumors. No difference in efficacy has been shown between single 
stent placement in the left or the right system. Really, the necessity to 
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ensure the drainage of both systems, including additional endoscopic or 
percutaneous stent, if necessary, pertains more to the prevention of 
procedure-induced cholangitis caused by contrast injection in undrained 
biliary branches than to effective palliation. Generally, if both lobes are 
imaged with contrast during cholangiography bilateral stenting reduces the 
potential sequelae of cholangitis in contaminated but undrained areas. If 
contrast does not contaminate both sides then unilateral stenting should be 
sufficient.   Patients with multiple intrahepatic strictures may not benefit 
from any type of drainage procedure if several segments (>1/4) always 
remain undrained. In the absence of intractable symptoms, these patients 
should avoid endoscopic measures, as the risk of inducing cholangitis 
outweighs benefits from endoscopic drainage.  
Patient preparation  
The patients should have an intravenous line for administration of 
sedatives, antibiotics and hydration. Antibiotic coverage is mandatory, 
particularly in those patients with more complex strictures (Bismuth type 
III and IV). Prophylaxis can be given as a single, adequate dose shortly 
before the procedure and should be continued for 4-5 days after the 
procedure. Escherichia coli, and to a lesser extent, Klebsiella spp. (gram-
negative bacteria) and gram-positive Enterococcus spp. are the most 
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common organisms in bile. Therefore, antibiotics should be aimed mainly 
at gram-negative bacteria with good penetration in liver tissue and bile. 
Ciprofloxacin is currently the first choice of antibiotic. In case of 
cholangitis, piperacillintazobactam is advisable, Patients should be 
routinely sedated with diazepam or midazolam, sometimes combined with 
fentanyl or pethidine. The patients should be monitored by an assistant and 
by mechanical methods including pulse oximetry. Supervision by an 
anesthetist may be required.  
MRCP and CT-guided stent implantation. 
 Recent reports describe the utility ofMRCP or CT imaging to guide 
selection of the target lobe for subsequent endoscopic stenting, often 
without use of contrast27. MRCP or CT images are used to confirm the 
diagnosis of Klatskin tumor to exclude other biliary diseases and to 
demonstrate the stenoses as well as dilation of proximal liver segments.  
 The left or right main hepatic duct is chosen for stent insertion, 
depending on the number of drainable liver segments. Subsequent to 
MRCP selective endoscopic retrograde contrast injection is deliberately 
limited to the distal end of the malignant tumor stenosis. Thereafter, 
sphincterotomy is generally performed, the papillotome or a catheter is 
advanced to the distal margin of the stricture and a guidewire (hybrid or 
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hydrophilic) is advanced, under fluoroscopic guidance, in the direction of 
the duct preselected for drainage based on prior imaging. Once the 
guidewire passes through the stricture, it is advanced as deeply as possible 
into that lobe. Then a catheter is advanced over the guidewire and through 
the stricture as far as possible, the guidewire is removed, and as much bile 
as possible is aspirated to decompress the accessed duct. Contrast is 
injected with the catheter and the unilateral cholangiogram is completed. 
Subsequently, a stiff guidewire is substituted for the initial guidewire and 
the catheter removed, leaving the guidewire in that duct for the remainder 
of the procedure until final stent deployment. Thereafter, if necessary, 
dilation of the malignant stenosis is performed using either balloon 
catheters or bouginages. If histological diagnosis is not already 
establislied, sampling is performed with a biopsy forceps and cytology 
brush. Finally a plastic or a metal stent is inserted to decompress the 
proximal ductal system. If bilateral stent placement was planned, 
immediately after insertion of the first guidewire a second guidewire is 
inserted into the contralateral side, stents are placed sequentially into the 
left and then the right hepatic ducts over dual guidewires.  
Unilateral random stent implantation  
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MRCP images are used to confirm the diagnosis of Klatskin’s 
tumor, to exclude other biliary diseases, and to demonstrate the stenoses, 
as well as dilation of proximal liver segments. Contrast injection at ERCP 
is deliberately limited to the extrahepatic bile duct distal to the tumor. 
Then, sphincterotomy is performed in all cases, and a guidewire is 
subsequently advanced through the malignant stenosis into the duct that is 
technically easiest to access. A catheter is then passed over the guidewire 
and through the stenosis, and, after removal of the guidewire, a unilateral 
cholangiogram is completed. Finally, a single plastic or metallic stent is 
deployed26.  
Contrast-free stent implantation  
Stents are placed in these patients under fluoroscopic guidance as 
follows: the stent assembly is passed over the guidewire above the 
suspected site of stricture and the stent is deployed at the desired site.  
Rendezvous technique  
An interventional radiologist passes a guidewire transhepatically down the 
bile duct and into the duodenum; this wire is then grasped by the 
endoscopist to place stents in the bile duct. The combined percutaneous-
endoscopic approach has been reported by many groups. The rationale is 
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that the complications should be lower than those with a purely 
percutaneous approach, since only small catheters are passed through the 


















1. To Study the causes of Malignant Biliary obstruction  
2. To  Study the success rate of endoscopic stenting in patients with 
malignant biliary obstruction.  
3. To Study the reason for failure in endoscopic stenting.  
4. To  Study the morbidity and  mortality of endocopic Biliary stenting. 
5. To Study the effectiveness of 7F and 10F in endoscopic palliation of 
jaundice. 
6. To Study the difference in patency rates of 7F and 10F plastic stent.  
7. To Study the complication rate between 7F and 10F endocopic stenting. 
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MATERIALS AND METHODS 
 The Study was conducted in Department of Digestive Health and 
Disease  (DDHD) a superspeciality department with rich heritage located in 
Government peripheral hospital, Anna Nagar, Chennai, attached to 
Government Kilpauk Medical College, Chennai.  
 The study was conducted in DDHD inpatients and patients referred 
from Government Kilpauk Medical College (Surgical GastroEnterology, 
General Surgery), Government Royapettah Hospital (Surgical Gastro 
Enterology, General Surgery), Government General Hospital (Surgical 
GastroEnterology, General Surgery).The study period was from December 
2007 to December 2009.  
Patients with Malignant Biliary obstruction were divided in to two groups  
(1) Proximal Biliary Obstruction  
(2) Distal Biliary Obstruction .  
After ERCP stenting patients with 7F plastic stent were compared with 
patients with 10F plastic stents.  
INCLUSION AND EXCLUSION CRITERIA : 
 All patients with Malignant biliary obstruction with informed 
consent were included. 
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 Candidates not willing were excluded.  
 Candidates not fit for ERCP procedure were excluded. 
 Patients in whom benign cause was suspected were excluded. 
We used Duodenoscope of length 156cm working channel diameter 
of 4.2mm, field of view 1100 (Model No.ED341C Batch No.A120052) 
with a PENTAX video processor EPK 150C input 100-240V-50/60HZ 
ranging 300 VA max. 
 We used ERBE endocut (Model ICC 200 EA INT) for Biliary 
sphincterotomy with cutting current 120 effect 3 without coagulation. 
ACCESSORIES  
 Cannula (Triple Lumen with curved tip),  
 Guidewire Zebra 0.035 450 cm (Bavarianwire – Mediglobe) X wire 
(0.025, 0.035 – Conmed),  
 Wilson cook triple lumen bow sphincterotome, Triple lumen needle 
knife sphincterotome, 
 Sohendra Biliary dilatation catheter (7F, 10F)  
 OASIS 10 Fr. (One action Stent introduction system)  
 Stent pusher for 7F stent 
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 Biliary Stent 
o Size – 7F, 10F 
o Model – Amsterdam (Straight), Pigtail 
o Length – 7cm, 10 cm, 12cm 
 Cholangiogram done using IOHEXOL USP equiv to 350 mg. of 
Iodine (Omnique)  
Statistical Methods 
 The statistical software package SPSS for windows version 15 (SPSS 
Inc., Chicago, III) was used to analyse the date, mean, S.D. were used to 
summarise data for continuous variables whereas percentages were used 
for categorical variables.   
Patients presenting with Malignant biliary obstruction were 
investigated with  
 Complete hemogram 
 Blood Sugar 
 Urea creatinine 
 Liver function test 
 USG Abdomen 
 CT Abdomen,  
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 MRCP,  
 EUS 
Preparation  
Injection Vitamin K was given for 3 days.Injection Ciprofloxacin and 
Metronidazole IV  was given before the procedure and continued for 3 
days.Intravenous Dextrose normal saline was given for 4 hours before 
the procedure at 150ml./hr.The  procedure was explained in detail and 
informed written consent obtained.After over night fasting patient was 
taken to ERCP theatre and placed in prone position. 
 Sedation and Premedication– Injection Pentazocine 25mg., Injection 
Promethazine 50 mg., Injection Hyoscine 2 amp., in midazolam 2 - 5 
mg.  
 Duodenoscopy was done and ampulla visualized, if growth or 
ulceration visualized biopsy was taken  then  selective CBD cannulation 
was done using cannula or bow sphincterotome  and 0.35 guidewire (in 
tight stricture 0.25 guidewire). If guidewire entered repeatedly into 
pancreatic duct, then pancreatic duct stent was  placed and then 
cannulation of CBD was  attempted . Then bow sphicterotomy was 
done. 
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 Our endoscopists performed stenting by no contrast technique and 
unilateral random biliary stenting in most of the cases. If cholaniogram 
was necessary it was done using minimum of contrast. 
 After placing guidewire into right or left system using 
fluoroguidance, dilatation  was done using 7Fand 10F Sohendra Biliary 
dilators as  required.Then 10F x 10 cm straight or double pigtail stent 
was  placed using OASIS (One Action Stent Introduction System). For 
placing 7F stent stent pusher was used. 
 For most of the patients double pigtail stents were used. Our 
endoscopists felt straight stent may not be of adequate length to cross 
the stricture and  the chance of migration  was more compared to pigtail 
stents. 
 After placing the stent across the malignant  stricture, bile flow  was 
ensured. Stent position was  confirmed fluoroscopically. Patients were  
monitored for any immediate post procedure complications. After 6 hrs. 
patients were  given clear fluids and then diet  was slowly advanced. 
 In the next 2 days patients were monitored for complications like 
post sphincterotomy bleeding, cholangitis pancreatitis, perforation, stent 
migration, and investigated accordingly. 
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 After 1 week patients were reviewed as outpatient with clinical 
history for improvement in pruritis, jaundice, cholangitis and sense of 
well being.They  were monitored objectively with liver function test and 
ultrasound abdomen. 
 Patients were said to have adequate drainage if S. Bilirubin fell by 
0.5 mgs.% per day31. Serum Bilirubin was monitored 7 days after  
endoscopic stenting. Patients were  observed till 30 days post procedure 
for any mortality. 
 Patients were discharged with advice to turn up  for stent exchange if 
they developed  increasing jaundice and fever with chills.Patients  were  
not offered 3 monthly regular exchange. Long term follow up was done 










Number of Patients 60 
Male  36 
Female  24 
M:F Ratio  3:2 
Mean Age  58.6     
Age Range 32-80 
Age range in Males  35-80 
Age range in Females  32-80 
Ampullary malignancy  22 
Head of pancreas growth 8 
Distal cholangiocarcinoma 15 
Gall bladder carcinoma 5 
Hilar cholangiocarcinoma 8 
Node causing obstruction 2 
No of  patients with Proximal Malignant Biliary Obstruction 45  (75%) 
No of  patients with Distal Malignant Biliary Obstruction  15  (25%) 
Success rate of  endoscopic plastic Stenting in all patients  68.33% 
Success rate of  stenting in proximal Malignant Biliary Obstruction 60% 
Success rate of stenting  in distal Malignant Biliary Obstruction  78.0% 
Number of cases with 10F. Plastic stent 16     




    
Number of days of patency for 7F Plastic stent  61 days  
Number of days of patency For 10F  Plastic stent  217 days  
Immediate Complication  6/60  10% (3 minor, 3 Moderate) 
30 day mortality    Nil 
Exchange 6/41 ,  













Socioeconomic status : 
 Most of the patients were from Government hospitals in Chennai. All 
were from lower socioeconomic status. 
Risk Factor : 
 Age group of patients range from 32-80. Mean age was 58.6.  
Age group of male 35-80, with mean age of 56.80. Age group of female 
range from 32-80 with mean age of 61.29. P value 0.132. Statistically not 
significant . M : F ratio of all patients was 3 : 2. The M F ratio of Gall 
Bladder carcinoma was also 3 : 2.  
Among 8 patients with pancreatic carcinoma 5 patients were  smokers. 
Chronic liver disease was seen in one patient with hilar 
Cholangiocarcinoma and one patient with distal cholangiocarcinoma. 
Among the patients with Malignant Biliary  Obstruction causes due to 
distal MBO were 45/60 and causes due to proximal MBO were 15/60. 
Etiology were  
                         Ampullary carcinoma 22 (36.6%) 
 Distal cholangiocarcinoma 15 (25%) 
 Head of Pancreas carcinoma 8 (13.3%) 
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 Hilar Cholangiocarcinoma 8 (13.3%) 
 Gall Bladder Carcinoma 5 (8.3%) 
 Lymph node causing hilar obstruction  2 (3.3%) 
Clinical features 
Commonest presentation was jaundice 100% (60/60).The other 
presentations were anorexia and loss of weight 54/60 (90%), pruritus 50/60 
patients (83.3%),pale stools  45/60 patients (75%), abdomeninal  pain 
16/60 patients (26.6%) , Cholangitis 9/60 (15%)and Malena  3/60(5%). 
 Hepatomegaly was seen in 41/60 patients and gall bladder was 
palpable in 21/60 (35%). In patients with proximal Malignant Biliary 
Obstruction hepatomegaly was palpable in 30/45 patients compared with 
11/15 in patients with distal Malignant Biliary Obstruction. In patients with 
distal Malignant Biliary Obstruction GB was palpable in 16/45 (35%) 
patients compared with 5/15 (35%) patients in proximal Malignant Biliary 
Obstruction. There was no statistical significance between these two 
groups. 
Endoscopic stenting 
        Among  the 41 patients who were successfully stented 29 patients 
were  stented in  first sitting and 10 patients were stented in second sitting. 
In 2 patients stenting was successful only in third sitting. 
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Biliary Bow Sphincterotomy was done in 30 patients, needle knife 
Sphincterotomy used in 15 patients, pancreatic stent was placed in 5 
patients. 
Method of Stent placement 
        Out of 41 patients stented contrast free stent implantation was done in 
34 patients. Among these  34 patients  MRCP assisted stenting was done in 
7 patients. In rest of the patients fluoro assisted non contrast technique was 
used. In  the remaining  7 patients cholangiogram was done. 
Stenting was successful in 41/60 patients with overall success rate of  
68.33%.Success rate for proximal MBO was (78.0%)32/41 compared with 
success rate of (60%) 9/15 for distal malignant biliary obstruction, with P 
value of 0.423 (statistically not significant). Among the patients where 
endoscopic stenting failed, the causes of  failure include 
 Repeated entry of guidewire into pancreatic duct 6/19 
 Tight stricture                                                         5/19 
 Non visualization of ampulla                                 3/19  
 Anatomical defects                                                2/19 
 Diverticulum                                                          1/19 
 Reason not known                                                  2/19   
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Post procedure complications 
Immediate complication rate was 10% (6/60) 
Most common complication was cholangitis (3) followed by pancreatitis 
(1), perforation (1) and   stent migration (1). Stent migration was managed 
with repeat stenting 2 days later. All other patients were managed 
conservatively. One patient went against medical advice. 
 Complication rate in patients with proximal malignant biliary 
obstruction was (83.3%)5/6 compared to (16.7%)1/6 in patients with distal 
malignant bilary obstruction  with P value 0.39163 ( not significant).  
Complication following 7F stenting occurred in 3 patients compared to  
1 patient following 10F stenting with  P Value 0.699( not significant). 
There was no mortality at 30 days in any group followed. 
Review visit  
Mean Serum Bilirubin  (total) before stenting was 14.44 mg%and after 
stenting was 7.19%. Drainage was obtained in all patients stented with 7F 
or 10F plastic stents. 
Repeat Serum Bilirubin  (total) at 7 days following 7F stenting and 10F 
stenting was   7.1mg% and  5.3mg% respectively. 
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Stent exchange 
Only 6 patients came for stent exchange among them 2 underwent stenting 
twice. The shortest duration of  stent patency was 40days,longest duration 
of stent patency was 10 months 
Mean no of days for 1st exchange was 61 days for patients with 7F stent 
and 217 days for patients with 10F stent P value <0.001 (significant) 
Stent exchange was done in 2/45 in patients with distal obstruction 
compared with 4/15 in patients with proximal obstruction P value not 
significant. 
Long Term Follow up 
 13 patients had long term follow up, shortest duration was 1 month 
and longest duration was 15 months mean of 3.615 months. Among them 8 






       PROXIMAL MALIGNANT BILIARY OBSTRUCTION Vs  
      DISTAL MALIGNANT BILIARY OBSTRUCTION 
 Proximal Distal P Value Significance 
Male 23 11 
0.132 N.S. 
Female 22 4 
Success 32 9 
0.423 N.S. 
Failure 13 6 
 
1st sitting 26 10 
0.64551 N.S. 2nd sitting 17 5 
3rd sitting 2 0 
Hepatomegaly 
palpable 30 11 
0.630 N.S. 
Non palpaple 15 4 
Gall Bladder 
palpable 16 5 
0.875 N.S. 
nonpalpable 29 10 
Comorbid Illness 
GB Stone 2 0 
0.49 N.S. GB & CBD Stone 3 - 






7F VS 10F PLASTIC STENTS 
 7 F Stent 10 F Stent P Value Significance  
Complications 
0.699 N.S. Cholangitis 2 1 
Pancreatitis 1 0 
Number of Attempts for Endoscopic stenting 
0.65087 N.S. 
1st sitting 19 10 
2nd sitting 5 5 
3rd sitting 1 1 
Stent Exchange 
No. of Patients 5 3 
0.001 Significant 










Stent Migration 1 
Bleeding Nil 
TOTAL 6/60  ( 10%) 
 
LATE COMPLICATIONS AFTER STENTING 
30 Day Mortality Nil 








ETIOLOGY OF MALIGNANT BILIARY OBSTRUCTION 
 




Distal Cholangiocarcinoma 15 (25%) 
Head of Pancreas Malignancy 8 (13.3%) 




Gall Bladder Carcinoma 5  (8.3%) 











 In this  study all patients were from lower socioeconomic status so 
the epidemiological aspect of this  study will reflect a group of people from 
lower socio economic status. 
 M : F ratio in this study was 3 : 2. Age group of patients 32-80. 
Mean age was 58.6. Age group of male patients range from 35-80, with 
mean age of 56.80. Age group of female patients  range from 32-80 with 
mean age of 61.29. 
 Randi G et al29 in their study described mean age of patients with 
biliary tract cancer as 56.76. Yogesh Batra33 descried a M : F ratio of 
0.36:1 in Gall Bladder carcinoma in their study. The M.F. ratio of Gall 
Bladder carcinoma in this study was 3 : 2. The difference could be could be 
due to fewer number of patients in this study. 
 Barbhuiya30 (et al) described M : F ratio of 3 : 2 in their single centre 
study in central India. This was very similar to  the observation in this 
study. 
In this study 5 patients with pancreatic carcinoma had smoking history. 
Ghadirian24 et al have described smoking as a risk factor for pancreatic 
carcinoma with two fold relative risk in their study.  
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In this study one patient with  hilar cholangiocarcinoma  and one 
patient with distal cholangiocarcinoma was associated with HBV related 
chronic liver disease. Shaib Y et al23 have described chronic liver disease as 
one of the risk factor for cholangiocarcinoma.  
 In this study commonest cause of malignant biliary obstruction was 
ampullary carcinoma 22 (36.6%) followed by distal cholangiocarcinoma  
15 (25%), hilar cholangiocarcinoma 8(13.3%), head of pancreas 
malignancy8 (13.3%),Gall bladder carcinoma 5(8.3%)and lymph node 
causing hilar obstruction2(3.3%) 
 Ibrahim A et al34 in their study of 72 patients described incidence of 
cholangiocarcinoma (proximal and distal) in 31 patients 43%, pancreatic 
adenocarcinoma in  23 patients (31.9%), followed by Gall Bladder cancer 
in 5 patients(8.3%).In their study incidence of cholangiocarcinoma was 
similar to this study, whereas ampullary carcinoma was less common in 
their study, the increased incidence of ampullary adenocarcinoma in this 
study could be attributed to lack of biopsy confirmation in all patients. 
 In this study commonest presentation was jaundice 100% followed 
by anorexia and loss of weight 90%, pruritis 50/60 (83.3%), pale stools 
45/60 75%, abdominal pain 16/60 (26.6%)and malena3/60(5%). 
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 Giovanni D De Palma et al31 described jaundice in 100%, pruritis 
(100%) anorexia and weight loss in 50%. 
 The increased incidence of anorexia and weight loss in this study 
could be attributed to the late presentation in the patients  
 In this study the sensitivity of Biliary Brush cytology was 25%. 
Hema Govil25, CJR Stewart39 reported Biliary Brush cytology sensitivity of 
68% and 59.8%  with specificity of 100% and 98% respectively. The lower 
sensitivity in this study could be explained by fewer number of patients in 
this study and reused Biliary Brush Cytology forceps. 
 Overall success rate of patients undergoing endoscopic plastic 
stenting was 68.33% patients with distal malignant biliary obstruction had a 
success rate of (78.0%) and those with proximal malignant biliary 
obstruction had a success rate of  (60%).  
 Ibrahim A et al34 in their single centre experience described a overall 
success rate of (77.8%) which is similar to this study. 
 In more recent studies from west like the one by Giovanni D De 
Palma et al 31 success rate of 100%  was described. This may be due to 
single use of accessories and relatively earlier presentation of patients to 
the endoscopic palliation. 
 54 
 In this study immediate complication rate was 10% (6/60),with 
cholangitis being the commenest  with incidence rate of 5% (3/60), with no 
30 day mortality. S.S. Saluja, Manpreet Gulati et al32  have described in 
their study cholangitis rate of (11%). 
 Giovani D De Palma et al31  in their study described no cholangitis 
and no 30 day mortality. The absence of cholangitis in their study could be 
attributed to no contrast technique in their study compared to usage of 
contrast   in 7 patients in this study. 
  In this study mean serum total bilirubin was  14.44 mg.% before 
stenting  and 7.19 mg% after stenting. The mean serum total bilirubin after 
7F plastic stenting was 7.64+3.6mg% compared to mean serum bilirubin 
value of 5.31+2.13mg% after 10 F plastic stenting.  
Drainage occurred in all patients after 10F and 7 F stent in each group. 
Virendera Singh36 and Sigh V37 have described similar results in their study 
(100%) drainage. 
Giovani et al31  in their study described a mean serum total bilirubin value 
of  15.8 + 9.2mg% before stenting and  a mean serum bilirubin value of 4.0 
+ 2.1mg% after stenting. 
 Among the patients whom underwent stent exchange  once stent 
patency was 61 days for 7F stenting and 217 days for 10F stenting in this 
study which was statistically significant.  
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 Moller Pedersen et al38  in their observation described mean patency 
days for 7F as 67 days and 144 days for 10F stenting which was similar to 
the observation in  this study. 
 A Speer et al28  have described patency rate of 32 weeks for 10F 
compared with 12 weeks for 7F which is also similar to this study. 
 Complication rate among patients  stented with 7F plastic stents and 
10F plastic stents were similar in my study. However A Speer et al have 
described less complication rate 5% in patients stented with  10F plastic 
stents  compared to 34% in  patients stented with 7F plastic stents. 
 Moller Pedersen et al38  have described  immediate complication rate 
of 13.9% after 7F plastic stent, and 16.7%  after 10F plastic stent.The 
reason for  similar rate of complications between patients stented with 7F 









1. Most common cause  of malignant biliary obstruction in this study 
was ampullary adenocarcinoma followed by  distal 
cholangiocarcinoma, hilar cholangiocarcinoma, head of pancreas 
malignancy, Gall Bladder carcinoma and lymph node causing hilar 
obstruction .  
2. Over all  success rate of all patients with Malignant Biliary 
Obstruction was 68.6% with success rate of  78% for patients with 
distal Malignant Biliary Obstruction and 60% for patients with 
proximal Malignant Biliary Obstruction cases.  
3. Most common reason for failure of endoscopic stenting in patients 
with malignant biliary obstruction  was repeated entry of guidewire 
into pancreatic duct followed by tight stricture,nonvisualization of 
ampulla,   anatomical difficulties and periampullary diverticulum. 
4. Immediate complication rate was 10% with no mortality. Cholangitis 
being the commonest complication followed by pancreatitis, 
perforation, stent migration in one patient each. 





6. Mean number of days of stent patency after 10F stent was 217 days 
and 61 days after 7F which was statistically significant. 
7. Complication rate between patients treated with 7F Plastic stent and  
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   CT Abdomen 
   MRCP 
   EUS 
PROCEDURE 
   Sphincterotomy 
   Dilatation 
   Cholangiogram 
   7F or 10 F stenting 
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Post procedure complication 
   Cholangitis 
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   Other complication 
 
Review visit at 7 days 
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Stent Exchange 
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SUCCESS RATE OF STENTING ACCORDING TO SITE 
PROCEDURAL SUCCESS RATE OF STENTING IN ALL PATIENTS 
78% 
60% 
Success rate for endoscopic stenting in distal 
MBO 








































































 Triple Lumen BOW Sphincterotome 
 
























































7F Double Pigtail Stent 




























7F Double Pigtail Stent in Position Draining white bile 
